These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 82705)

  • 1. Subcutaneous desferrioxamine in homozygous beta-thalassaemia.
    Silvestroni E; Bianco I; Graziani B; Carboni C; Costantini S
    Lancet; 1978 Nov; 2(8100):1149-50. PubMed ID: 82705
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevention of iron loading in transfusion-dependent thalassaemia.
    Pippard MJ; Letsky EA; Callender ST; Weatherall DJ
    Lancet; 1978 Jun; 1(8075):1178-81. PubMed ID: 77945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
    Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral desferrioxamine in young patients with thalassaemia.
    Kattamis C; Fitsialos J; Sinopoulou C
    Lancet; 1981 Jan; 1(8210):51. PubMed ID: 6109092
    [No Abstract]   [Full Text] [Related]  

  • 5. Intensive iron-chelation in thalassaemia.
    Br Med J; 1978 Sep; 2(6140):782-3. PubMed ID: 698731
    [No Abstract]   [Full Text] [Related]  

  • 6. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I; Hatzidimitriou-Papazacharia K; Spiliotopoulou J; Tsagarakis N; Digenopoulou E
    Birth Defects Orig Artic Ser; 1988; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract]   [Full Text] [Related]  

  • 7. [Desferrioxamine in thalassemia].
    Biener R; Freundlich E; Rachmilewitz E
    Harefuah; 1983 May; 104(10):438-40. PubMed ID: 6629159
    [No Abstract]   [Full Text] [Related]  

  • 8. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH; Markenson A; Miller DR; Chang H; Bestak M; Meyers P; Pisciotto P; Rifkind A
    J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term administration of desferrioxamine in thalassaemia major.
    Seshadri R; Colebatch JH; Gordon P; Ekert H
    Arch Dis Child; 1974 Aug; 49(8):621-6. PubMed ID: 4278421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Site of subcutaneous desferrioxamine injection is the initial site of post-transfusion urticaria in multi-transfused beta-thalassaemia major patients.
    Daar S; Ghosh K; Nirmala V
    Clin Lab Haematol; 2000 Feb; 22(1):55-6. PubMed ID: 10819612
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduction of iron overload in thalassemia.
    Piomelli S; Graziano J
    Birth Defects Orig Artic Ser; 1982; 18(7):339-46. PubMed ID: 7159742
    [No Abstract]   [Full Text] [Related]  

  • 12. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
    Cossu P; Toccafondi C; Vardeu F; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Bertolino F; Loi A; De Virgiliis S; Cao A
    Eur J Pediatr; 1981 Nov; 137(3):267-71. PubMed ID: 7318837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Continuous subcutaneous deferoxamine infusions in thalassemia major. Improvement in glucose tolerance].
    Krüger N; Stubbe P; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1986 May; 111(18):698-701. PubMed ID: 3486106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.
    De Virgiliis S; Cossu P; Toccafondi C; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Loi A; Bertolino F; Cao A
    Am J Pediatr Hematol Oncol; 1983; 5(1):73-7. PubMed ID: 6859457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Continuous subcutaneous deferoxamine treatment in thalassemia major. Decrease of hemosiderosis and improvement of liver function].
    Krüger N; Ullrich D; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1985 Nov; 110(48):1848-51. PubMed ID: 4064938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular toxicity of high-dose intravenous desferrioxamine.
    Davies SC; Marcus RE; Hungerford JL; Miller MH; Arden GB; Huehns ER
    Lancet; 1983 Jul; 2(8343):181-4. PubMed ID: 6135026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary iron excretion in thalassaemia after desferrioxamine administration.
    Seshadri R; Colebatch JH; Fisher R
    Arch Dis Child; 1974 Mar; 49(3):195-9. PubMed ID: 4825624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current therapy of Cooley's anemia. A decade of experience with subcutaneous desferrioxamine.
    Giardina PJ; Grady RW; Ehlers KH; Burstein S; Graziano JH; Markenson AL; Hilgartner MW
    Ann N Y Acad Sci; 1990; 612():275-85. PubMed ID: 2291555
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined long-term treatment of hemosiderosis with desferioxamine and DTPA in homozygous beta-thalassemia.
    Constantoulakis M; Economidou J; Karagiorga M; Katsantoni A; Gyftaki E
    Ann N Y Acad Sci; 1974; 232(0):193-200. PubMed ID: 4528481
    [No Abstract]   [Full Text] [Related]  

  • 20. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.
    Hoffbrand AV; Gorman A; Laulicht M; Garidi M; Economidou J; Georgipoulou P; Hussain MA; Flynn DM
    Lancet; 1979 May; 1(8123):947-9. PubMed ID: 87616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.